OTCMKTS:STDAF - STADA Arzneimit/AKT o.N. Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$87.80 -2.55 (-2.82 %)
(As of 12/18/2018 02:03 PM ET)
Previous Close$90.35
Today's Range$87.80 - $87.80
52-Week Range$90.35 - $108.40
Volume300 shs
Average Volume13 shs
Market Capitalization$5.63 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.76
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH.

Receive STDAF News and Ratings via Email

Sign-up to receive the latest news and ratings for STDAF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:STDAF
Previous SymbolNASDAQ:STDAF
CUSIPN/A
Phone49-6101-6030

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.61 billion
Price / Sales2.09
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares62,340,000
Market Cap$5.63 billion
OptionableNot Optionable

STADA Arzneimit/AKT o.N. (OTCMKTS:STDAF) Frequently Asked Questions

What is STADA Arzneimit/AKT o.N.'s stock symbol?

STADA Arzneimit/AKT o.N. trades on the OTCMKTS under the ticker symbol "STDAF."

When is STADA Arzneimit/AKT o.N.'s next earnings date?

STADA Arzneimit/AKT o.N. is scheduled to release their next quarterly earnings announcement on Thursday, December 20th 2018. View Earnings Estimates for STADA Arzneimit/AKT o.N..

What is the consensus analysts' recommendation for STADA Arzneimit/AKT o.N.?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STADA Arzneimit/AKT o.N. in the last year. There are currently 2 sell ratings for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for STADA Arzneimit/AKT o.N..

Has STADA Arzneimit/AKT o.N. been receiving favorable news coverage?

News articles about STDAF stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. STADA Arzneimit/AKT o.N. earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an effect on the stock's share price in the next few days.

Who are some of STADA Arzneimit/AKT o.N.'s key competitors?

Who are STADA Arzneimit/AKT o.N.'s key executives?

STADA Arzneimit/AKT o.N.'s management team includes the folowing people:
  • Mr. Mark Burgess Keatley MBA, MA, MPhil, CFO & Member of Exec. Board (Age 61)
  • Mr. Peter Goldschmidt, Chairman of the Exec. Board & CEO (Age 54)
  • Mr. Miguel Pagan Fernandez, CTO & Member of Exec. Board (Age 53)
  • Mr. Sebastian Kramer-Bach, Exec. VP of Corp. Communication (Age 43)
  • Ms. Kay Reubelt, Director of Investor Relations

How do I buy shares of STADA Arzneimit/AKT o.N.?

Shares of STDAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is STADA Arzneimit/AKT o.N.'s stock price today?

One share of STDAF stock can currently be purchased for approximately $87.80.

How big of a company is STADA Arzneimit/AKT o.N.?

STADA Arzneimit/AKT o.N. has a market capitalization of $5.63 billion and generates $2.61 billion in revenue each year.

What is STADA Arzneimit/AKT o.N.'s official website?

The official website for STADA Arzneimit/AKT o.N. is http://www.stada.de.

How can I contact STADA Arzneimit/AKT o.N.?

STADA Arzneimit/AKT o.N.'s mailing address is Stadastrasse 2-18, Bad Vilbel 2M, 61118. The company can be reached via phone at 49-6101-6030.


MarketBeat Community Rating for STADA Arzneimit/AKT o.N. (OTCMKTS STDAF)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  332
MarketBeat's community ratings are surveys of what our community members think about STADA Arzneimit/AKT o.N. and other stocks. Vote "Outperform" if you believe STDAF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STDAF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/18/2018 by MarketBeat.com Staff

Featured Article: How a Put Option Works

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel